The vaccine against avian influenza of the H9N2 subtype is inactivated and emulsified. The vaccine is made from the extraembryonic fluid of chicken embryos infected with the H9N2 strain of avian influenza virus, inactivated with formaldehyde, with the addition of the oil adjuvant ISA70, manufactured by SEPPIC, in a ratio of 30:70. In appearance, the vaccine is an emulsion from white to white-pink in color. When storing the vaccine, it is allowed to precipitate a dense white fraction with an emulsion clearing in the upper part of the vial, without separating the aqueous phase. The uniformity of the emulsion is restored by careful shaking. The vaccine is packaged in 10 cm3 (20 doses for chickens, 40 doses for chickens), 20 cm3 (40 doses for chickens, 80 doses for chickens), 100 cm3 (200 doses for chickens, 400 doses for chickens), 500 cm3 (1000 doses for chickens, 2000 doses for chickens) glass and/or polymer vials of appropriate capacity, hermetically sealed with rubber stoppers reinforced with aluminum caps. Storage for 18 months from the date of manufacture, subject to temperature conditions, freezing is not allowed.

The vaccine causes the formation of an immune response in chickens to the pathogens of avian influenza subtype H9, 28 days after a single application, lasting at least 6 months. The vaccine is harmless and has no medicinal properties.

Chickens from the age of 7 days and an adult bird are subject to vaccination no later than one month before the start of egg laying. In chickens, the vaccine is injected subcutaneously into the middle third of the neck or intramuscularly into the area of the pectoralis major muscle. The volume of the vaccine dose is 0.25 cm3 of the vaccine. Adult poultry should be vaccinated subcutaneously in the area of the middle third of the neck or intramuscularly in the area of the pectoralis major muscle with revaccination every 6 months. The volume of the vaccine dose is 0.5 cm3 of the vaccine. Before use, the vaccine is kept for 6-9 hours at a temperature of 20 ° C to 25 ° C.

28 days after vaccination, the intensity of immunity to the avian influenza virus of the H9N2 subtype is monitored by examining at least 25 blood serum samples from each poultry house in RTGA. Vaccination is considered successful if at least 80% of vaccinated birds have an antibody titer to the HP subtype H9 virus of at least 4log2 (1:16).

Low-pathogenic avian influenza (H9N2) and Newcastle disease inactivated emulsified vaccine. The vaccine is made from the extraembryonic fluid of chicken embryos infected with low-pathogenic avian influenza viruses (strain A/chicken/Siberia/200-05/2018/ H9N2) and Newcastle disease (La Sota strain), formaldehyde-inactivated oil adjuvant Montanide ISA 70 in a 30:70 ratio. In appearance, the vaccine is a homogeneous emulsion from white to white-pink in color. During storage of the vaccine, a slight delamination of the emulsion is allowed, with clearance on the top of the vial, without separation of the aqueous phase. The uniformity of the emulsion is restored by careful shaking. The vaccine is packaged in 10 cm3 (20 doses for chickens, 40 doses for chickens), 20 cm3 (40 doses for chickens, 80 doses for chickens), 100 cm3 (200 doses for chickens, 400 doses for chickens), 500 cm3 (1000 doses for chickens, 2000 doses for chickens) glass and/or polymer vials of appropriate capacity, hermetically sealed with rubber stoppers reinforced with aluminum caps. The shelf life of the vaccine is 18 months from the date of release, subject to the conditions of storage and transportation, freezing is not allowed.

The vaccine causes the formation of an immune response in chickens to the pathogens of low-pathogenic avian influenza (H9N2) and Newcastle disease, 28 days after vaccination, lasting at least 9 months.

The vaccine is intended for the prevention of low-pathogenic avian influenza (H9N2) and Newcastle disease in poultry farms of various growing areas, as well as for compulsory vaccination in disadvantaged and threatened farms in order to stop infections. The vaccine is injected subcutaneously into the middle third of the neck or intramuscularly into the area of the pectoralis major muscle in compliance with the rules of asepsis twice with an interval of 21-28 days. The volume of the vaccination dose for young chickens aged 1-30 days is 0.25 cm3; for poultry older than 30 days of age, 0.5 cm3. Before use, vials of the vaccine are kept for 3-4 hours at a temperature of 18-20 ° C.

28 days after the second vaccination, the immune system is monitored by examining at least 25 samples of avian blood serum from a poultry house or settlement in the hemagglutination inhibition reaction (RTGA). Vaccination is considered successful if at least 80% of vaccinated birds have an antibody titer of at least 4 log2 (1:16) for HP H9 and BN viruses.

The vaccine against Newcastle disease is an inactivated emulsion. The vaccine is made from the extraembryonic fluid of chicken embryos infected with the Newcastle disease virus (La Sota strain), inactivated with formaldehyde, with the addition of the oil adjuvant ISA70, manufactured by SEPPIC, in a ratio of 30:70. In appearance, the vaccine is an emulsion from white to white-pink in color. When storing the vaccine, it is allowed to precipitate a dense white fraction with an emulsion clearing in the upper part of the vial, without separating the aqueous phase. The uniformity of the emulsion is restored by careful shaking. The vaccine is packaged in 10 cm3 (20 doses for chickens, 40 doses for chickens), 20 cm3 (40 doses for chickens, 80 doses for chickens), 100 cm3 (200 doses for chickens, 400 doses for chickens), 500 cm3 (1000 doses for chickens, 2000 doses for chickens) glass vials or polymer vials of appropriate capacity, hermetically sealed with rubber stoppers reinforced with aluminum caps. Storage for 18 months from the date of manufacture, subject to temperature conditions, freezing is not allowed.

The vaccine causes the formation of an immune response in broilers to the causative agent of Newcastle disease, 14-21 days after a single application, lasting at least 6 weeks. When used twice with an interval of 21-28 days, the duration of immunity is at least 9 months. The vaccine is harmless and has no medicinal properties.

The vaccine is intended for the prevention of Newcastle disease in poultry farms of various types of cultivation, as well as for compulsory vaccination in disadvantaged and threatened farms in order to stop infections at least one month before the start of egg laying. In chickens, the vaccine is injected subcutaneously into the middle third of the neck or intramuscularly into the area of the pectoralis major muscle. The volume of the vaccine dose is 0.25 cm3 of vaccine for chickens 1-10 days. Adult poultry, starting from day 11, should be vaccinated subcutaneously in the middle third of the neck or intramuscularly in the area of the pectoralis major muscle with revaccination, based on the epizootic situation, in a volume of 0.5 cm3. Before use, the vaccine is kept for 6-9 hours at a temperature of 20 ° C to 25 ° C.

21 days after a single vaccination, the immune system is monitored by examining at least 25 blood serum samples from each poultry house in RTGA. Vaccination is considered successful if at least 80% of vaccinated birds have an antibody titer to the Newcastle disease virus of at least 4log2 (1:16).

The vaccine against Newcastle disease of the VII genotype is inactivated emulsion. The vaccine is made from the extraembryonic fluid of chicken embryos infected with the Newcastle disease virus· (strain "GVII"), inactivated with formaldehyde with the addition of the oil adjuvant Montanide ISA 70 in a ratio of 30:70. In appearance, the vaccine is a homogeneous emulsion from white to white-pink in color. During storage of the vaccine, a slight delamination of the emulsion is allowed, with clearance on the top of the vial, without separation of the aqueous phase. The uniformity of the emulsion is restored by careful shaking. The vaccine is packaged in 10 cm3 (20 doses for chickens, 50 doses for chickens), 20 cm3 (40 doses for chickens, 100 doses for chickens), 100 cm3 (200 doses for chickens, 500 doses for chickens), 500 cm3 (1000 doses for chickens, 2500 doses for chickens) glass and/or polymer vials of appropriate capacity, hermetically sealed with rubber stoppers, reinforced with aluminum caps. Storage for 18 months from the date of release, subject to temperature conditions, freezing is not allowed.

The vaccine causes the formation of an immune response in broilers to the causative agent of Newcastle disease, 14-21 days after a single immunization lasting at least 6 weeks. With double immunization of the repair and parent stock of chickens with an interval of 21-28 days, the duration of immunity is at least 9 months. The vaccine is harmless and has no medicinal properties.

The vaccine is intended for the prevention of Newcastle disease of the VII genotype in poultry farms of various types of cultivation, as well as for forced vaccination in disadvantaged and threatened farms in order to stop infection. The vaccine is injected subcutaneously into the middle third of the neck or intramuscularly into the area of the pectoralis major muscle in compliance with the rules of asepsis to broilers once, to repair livestock twice with an interval of 21-28 days. The volume of the vaccination dose for young chickens aged 1-10 days is 0.2 cm3, for poultry older than 11 days 0.5 cm3. Before use, vials of the vaccine, in order to reduce the viscosity of the oil to prevent post-vaccination reactions, are kept at least 6-10 hours at a temperature of 18-20 ° C.

21 days after a single vaccination of broilers and 28 days after the second vaccination of repair and parent poultry, immunity levels are monitored by examining at least 25 samples of avian blood serum from a poultry house or locality in the hemagglutination inhibition reaction (RTG A). Vaccination is considered successful if at least 80% of vaccinated birds have an antibody titer to Newcastle disease viruses of at least 5 log2 (1:32).

The vaccine is made from the extraembryonic liquid of SPF chicken embryos infected with the low-pathogenic avian influenza virus (strain H9N2 V-35) and Newcastle disease viruses (strain La Sota and GVII) inactivated with formaldehyde with the addition of the oil adjuvant Montanide ISA 70 in a ratio of 30:70. In appearance, the vaccine is a homogeneous emulsion from white to white-pink in color. During storage of the vaccine, a slight delamination of the emulsion is allowed, with clearance on the top of the vial, without separation of the aqueous phase. The uniformity of the emulsion is restored by careful shaking. The vaccine is packaged in 10 cm3 (20 doses for chickens, 50 doses for chickens), 20 cm3 (40 doses for chickens, 100 doses for chickens), 100 cm3 (200 doses for chickens, 500 doses for chickens), 500 cm3 (1000 doses for chickens, 2500 doses for chickens) glass and/or polymer vials of appropriate capacity, hermetically sealed with rubber stoppers reinforced with aluminum caps. The shelf life of the vaccine is 18 months from the date of release, subject to the conditions of storage and transportation, freezing is not allowed.

The vaccine causes the formation of an immune response in broilers to the pathogens of low-pathogenic avian influenza (H9N2) and Newcastle disease, 14-21 days after a single immunization lasting at least 6 weeks. With double immunization of the repair and parent stock of chickens with an interval of 21-28 days, the duration of immunity is at least 7 months.

The vaccine is intended for the prevention of Newcastle disease and low-pathogenic avian influenza (H9N2) in poultry farms of various growing areas, as well as for compulsory vaccination in disadvantaged and threatened farms in order to stop infections at least one month before the start of oviposition. The vaccine is injected subcutaneously into the middle third of the neck or intramuscularly into the area of the pectoralis major muscle in compliance with the rules of asepsis twice with an interval of 21-28 days. The volume of the vaccination dose for young chickens aged 1-10 days is 0.2 cm3, for poultry older than 11 days 0.5 cm3.Before use, vials of the vaccine are kept for 6-10 hours at a temperature of 18-20 ° C.

28 days after the second vaccination, the immune system is monitored by examining at least 25 samples of avian blood serum from a poultry house or settlement in the hemagglutination inhibition reaction (RTGA). Vaccination is considered successful if at least 80% of vaccinated birds have a titer of antibodies to HB and HP H9 viruses that is at least 4 log2 (1:16).

Inactivated emulsion vaccine against low-pathogenic avian influenza (H9N2) and Newcastle disease (strain "GVII"). The vaccine is made from the extraembryonic fluid of chicken embryos infected with the Newcastle disease virus (strain "GVII") and low-pathogenic avian influenza (strain H9N2) inactivated with formaldehyde with the addition of the oil adjuvant Montanide ISA 70 in a ratio of 30:70. In appearance, the vaccine is a homogeneous emulsion from white to white-pink in color. During storage of the vaccine, a slight delamination of the emulsion is allowed, with clearance on the top of the vial, without separation of the aqueous phase. The uniformity of the emulsion is restored by careful shaking. The vaccine is packaged in 10 cm3 (20 doses for chickens, 50 doses for chickens), 20 cm3 (40 doses for chickens, 100 doses for chickens), 100 cm3 (200 doses for chickens, 500 doses for chickens), 500 cm3 (1000 doses for chickens, 2500 doses for chickens) glass and/or polymer vials of appropriate capacity, hermetically sealed with rubber stoppers reinforced with aluminum caps. The shelf life of the vaccine is 18 months from the date of release, subject to the conditions of storage and transportation, freezing is not allowed.

The vaccine causes the formation of an immune response in chickens to the pathogens of Newcastle disease and low-pathogenic avian influenza (H9N2), 28 days after the second vaccination, lasting at least 9 months.

The vaccine is intended for the prevention of Newcastle disease and low-pathogenic avian influenza (H9N2) in poultry farms of various growing areas, as well as for compulsory vaccination in disadvantaged and threatened farms in order to stop infections, revaccination is carried out at least one month before the start of oviposition. The vaccine is injected subcutaneously into the middle third of the neck or intramuscularly into the area of the pectoralis major muscle in compliance with the rules of asepsis twice with an interval of 21-28 days. The volume of the vaccination dose for young chickens aged 1-10 days is 0.20 cm3; for birds older than 11 days of age, 0.5 cm3. Before use, vials of the vaccine are kept for 3-4 hours at a temperature of 18-20 ° C.

28 days after the second vaccination, the immune system is monitored by examining at least 25 samples of avian blood serum from a poultry house or settlement in the hemagglutination inhibition reaction (RTGA). Vaccination is considered successful if at least 80% of vaccinated birds have a titer of antibodies to HB and HP H9 viruses that is at least 4 log2 (1:16).

The medicinal product Eshrifag contains strains of bacteriophages Escherichia coli BF1351, Salmonella enteritidis BF-1354, Salmonella infantis BF-1355 and Salmonella typhimurium BF1356 (4%) in saline sodium chloride solution (96%). One commercial dose contains 1*107-9*108 (COMBAT) of phage particles of each bacteriophage strain. It does not contain genetically modified microorganisms. In appearance, it is a transparent liquid without color, odor and sediment. Eshrifag is produced in glass or polymer vials with an appropriate capacity of 100 cm3 containing 10,000 doses, respectively. Shelf life is 18 months from the date of release, subject to storage and transportation conditions. The medicinal product must be used within 72 hours after opening the vial.

Eshrifag is an antibacterial drug with the ability to specifically lyse pathogenic serotypes of Escherichia coli, as well as Salmonella enteritidis, Salmonella infantis, Salmonella typhimurium, Salmonella dublin, Salmonella gallinarum-pullorum. Salmonella choleraesuis. Salmonella bredeney, Salmonella reading, Salmonella virchow. The Escherichia coli and salmonella bacteriophages included in the preparation have a high rate of adsorption, reaching the target bacterial cells (by means of taxis), they multiply in them, while the concentration of phage particles increases. Coli-bacteriophages are active only against virulent cultures of Escherichia coli, and do not cause lysis of non-pathogenic Escherichia coli, which are the normoflora of the digestive system of animals and birds.

The drug is harmless, has therapeutic and preventive properties.

The drug is intended for the prevention and treatment of escherichiosis and salmonellosis in farm animals (pigs) and birds (chickens, turkeys, ducks, geese). Eshrifag is used for the treatment and prevention of escherichiosis and salmonellosis of birds (including pullorosis), colibacteriosis, edematous disease and paratyphoid of pigs, by individual or group methods - oral, aerosol and spray method (coarse spraying). The scheme of application provides for both preventive and curative use of the drug. There are no contraindications when using the drug in accordance with the approved instructions. Animal and bird slaughter products, as well as egg products after application

Medicinal product, used for food purposes without restrictions.

Efficiency assessment according to MP 3.5.1.0101—15

Listphage is a bacteriophage-based disinfectant that contains as an active ingredient a sterile cell-free filtrate of Listeria monocytogenes phagolysate LM1 - 1%, based on sterile saline solution - 99%. The titer of the bacteriophage is at least 1*109 BOE/ml (according to Grazia). It is intended for carrying out preventive and forced (current and final) disinfection of veterinary surveillance facilities using a biological method. In appearance, it is a transparent liquid, colorless and odorless, and has a neutral pH. The product mixes well with water in any ratio. It is packaged in glass or polymer vials with a capacity of 100 cm3.The shelf life of the product in the manufacturer's unopened packaging is 12 months from the date of manufacture, provided it is stored in a covered, ventilated warehouse, protected from moisture and sunlight, away from heating devices and open flames at temperatures from 2 ° C to 8 ° C. The shelf life of the opened product does not exceed 3 days, when stored at temperatures from 2 ° C to 8 ° C.

A bacteriophage-based disinfectant, it has the ability to specifically lyse Listeria spp strains.. The bacteriophages included in the disinfectant are stable in the external environment and compatible with other chemical disinfectants. According to the parameters of toxicity when applied to the skin and when injected into the stomach, according to GOST 12.1.007-76, the product belongs to the 4th class of low-risk substances. The range of resistance of bacteriophages to the pH of the external environment is 6-8. The resistance of bacteriophages to ambient temperature ranges from -80 to +55 ℃.

It is designed to ensure effective disinfection by biological method using bacteriophages of veterinary surveillance facilities. It can be used by aerosol or spray method, depending on the microbiological status and surface, and other features of the veterinary surveillance facility. It can be used by aerosol or spray method, depending on the microbiological status and surface, and other features of the veterinary surveillance facility. It is applied at least before or after 3-4 hours after the current (final) disinfection, the treatment can be carried out both "dirty" and "clean".

Evaluation of the effectiveness of the drug according to MP 3.5.1.0101—15.